Changes in HER2 Expression and Amplification Status Following Preoperative Chemotherapy for Gastric Cancer
| Autor: | Hiroshi Saeki, Tomoko Jogo, Yoshihiko Maehara, Eiji Oki, Ryota Nakanishi, Makoto Iimori, Sei Shu |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male Cancer Research Receptor ErbB-2 medicine.medical_treatment General Biochemistry Genetics and Molecular Biology 03 medical and health sciences 0302 clinical medicine Trastuzumab Stomach Neoplasms Gene duplication Preoperative Care Biomarkers Tumor Preoperative chemotherapy Medicine Humans Epidermal growth factor receptor Molecular Targeted Therapy skin and connective tissue diseases neoplasms Aged Cell Proliferation Pharmacology Chemotherapy Her2 expression biology business.industry Cancer Middle Aged Proto-Oncogene Proteins c-met medicine.disease ErbB Receptors Gene Expression Regulation Neoplastic Hepatocyte Growth Factor Receptor 030220 oncology & carcinogenesis Cancer research biology.protein 030211 gastroenterology & hepatology Female business medicine.drug Research Article |
| Zdroj: | In vivo (Athens, Greece). 32(6) |
| ISSN: | 1791-7549 |
| Popis: | Background It is essential to establish a strategy for second-line treatment for human epidermal growth factor receptor 2 (HER2)-positive gastric cancer; however, HER2 expression status after chemotherapy treatment is not routinely determined. Materials and methods We analyzed 25 cases of gastric cancer that received preoperative chemotherapy and selected the six pre-treatment samples that were HER2-positive. Pre- and post-treatment tumor samples were examined for HER2 expression, and for HER2, epidermal growth factor receptor (EGFR), and hepatocyte growth factor receptor (MET) gene amplification. Results Three patients had been treated with trastuzumab plus chemotherapy, and three patients with cytotoxic chemotherapy alone. Only one case that had an initial HER2 score of 3+ and had received trastuzumab plus chemotherapy remained HER2-positive after treatment. Decrease or loss of HER2 expression and amplification was observed in the other five patients. Amplification of EGFR or MET was not observed in any pre- or post-treatment specimens. Conclusion Our data suggest that trastuzumab plus chemotherapy or chemotherapy alone may induce loss of HER2 positivity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|